ABSTRACT
BACKGROUND: BMP9, originating from the liver, and BMP10 are circulating BMPs that preserve vascular endothelial integrity. We assessed BMP9, BMP10 and soluble endoglin (sEng) levels and their relationships to liver disease severity and associated pulmonary vascular syndromes in a cohort of well-characterised liver disease patients. METHODS: Plasma samples from patients with liver disease (n = 83) and non-disease controls (n = 21) were assayed for BMP9, BMP10 and sEng. Levels were also assessed in a separate cohort of controls (n = 27) and PoPH patients (n = 8). Expression of mRNA and immunohistochemical staining was undertaken in liver biopsy specimens. Plasma BMP activity was assessed using an endothelial cell bioassay. FINDINGS: Plasma BMP9 and BMP10 levels were normal in patients with compensated cirrhosis or fibrosis without cirrhosis, but markedly reduced in patients with decompensated cirrhosis, including those with hepatopulmonary syndrome (HPS) or portopulmonary hypertension (PoPH). Liver biopsy specimens revealed reduced mRNA expression and immunostaining for these ligands. Patient plasma samples with reduced BMP9 and BMP10 levels exhibited low BMP activity that was restored with exogenous BMP9. Endoglin mRNA expression was increased in cirrhotic livers and elevated circulating sEng levels in PoPH and HPS patients suggested increased endothelial sEng shedding in these syndromes. INTERPRETATION: Plasma BMP9 and BMP10 levels are reduced in decompensated cirrhosis, leading to reduced circulating BMP activity on the vascular endothelium. The pulmonary complications of cirrhosis, PoPH and HPS, are associated with markedly reduced BMP9 and BMP10 and increased sEng levels, suggesting that supplementation with exogenous ligands might be a therapeutic approach for PoPH and HPS.
Subject(s)
Bone Morphogenetic Proteins/blood , Down-Regulation , Endoglin/blood , Growth Differentiation Factor 2/blood , Hepatopulmonary Syndrome/blood , Hypertension, Pulmonary/blood , Liver Cirrhosis/pathology , Adult , Aged , Animals , Biopsy , Bone Morphogenetic Proteins/genetics , Case-Control Studies , Cell Line , Disease Models, Animal , Endoglin/genetics , Female , Growth Differentiation Factor 2/genetics , Humans , Hypertension, Pulmonary/genetics , Liver Cirrhosis/blood , Liver Cirrhosis/genetics , Male , Mice , Mice, Knockout , Middle Aged , Severity of Illness Index , Young AdultABSTRACT
BACKGROUND: Liver disorders may be associated with normal pulmonary hemodynamic, hepatopulmonary syndrome (HPS), or portopulmonary hypertension (POPH). In this study, we aimed to investigate the effect of the severity of liver dysfunctions on blood-borne variables, and pulmonary hemodynamic during repeated ventilation with hyperoxic and hypoxic gases. METHODS: Female Sprague Dawley rats were assigned into four groups of Sham (n = 7), portal vein ligation (PPVL, n = 7), common bile duct ligation (CBDL, n = 7), and combination of them (CBDL+ PPVL, n = 7). Twenty-eight days later, right ventricular systolic pressure (RVSP) and systemic blood pressure were recorded in anesthetized animals subjected to repeated maneuvers of hyperoxia (O2 50%) and hypoxia (O2 10%). Besides, we assessed blood parameters and liver histology. RESULTS: Liver histology score, liver enzymes, WBC and plasma malondialdehyde in the CBDL+PPVL group were higher than those in the CBDL group. Also, the plasma platelet level in the CBDL+PPVL group was lower than those in the other groups. On the other hand, the serum estradiol in the CBDL group was higher than that in the CBDL+PPVL group. All the above parameters in the PPVL group were similar to those in the Sham group. During ventilation with hyperoxia gas, RVSP in the CBDL+PPVL group was higher than the ones in the other groups, and in the CBDL group, it was more than those in the PPVL and Sham groups. Hypoxic pulmonary vasoconstriction (HPV) was not detected in both CBDL+PPVL and CBDL groups, whereas, it retained in the PPVL group. CONCLUSION: Severe liver damage increases RVSP in the CBDL+PPVL group linked to the high level of ROS, low levels of serum estradiol and platelets or a combination of them. Furthermore, the high RVSP at the noted group could present a reliable animal model for POPH in female rats.
Subject(s)
Hemodynamics , Hepatopulmonary Syndrome/physiopathology , Hyperoxia/physiopathology , Hypoxia/physiopathology , Liver Diseases/physiopathology , Pulmonary Circulation , Anesthesia, General , Animals , Biomarkers/blood , Blood Pressure , Common Bile Duct/surgery , Disease Models, Animal , Estradiol/blood , Female , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/pathology , Hyperoxia/blood , Hypoxia/blood , Ligation , Liver/pathology , Liver Diseases/blood , Liver Diseases/pathology , Malondialdehyde/blood , Nitric Oxide/blood , Portal Vein/surgery , Rats, Sprague-Dawley , Respiration, Artificial , Severity of Illness Index , Ventricular Function, Right , Ventricular PressureABSTRACT
One central factor in hepatopulmonary syndrome (HPS) pathogenesis is pulmonary vascular remodelling (PVR) which involves dysregulation of proliferation and migration in pulmonary microvascular endothelial cells (PMVECs). Growing evidence suggests that Apical/basolateral polarity plays an important role in cell proliferation, migration, adhesion and differentiation. In this study, we explored whether cell polarity is involved and critical in experimental HPS rats that are induced by common bile duct ligation (CBDL). Cell polarity related proteins were analysed in CBDL rats lung and PMVECs under the HPS serum stimulation by immunofluorescence assay. Cdc42/PTEN activity, cell proliferation and migration and Annexin A2 (AX2) in PMVECs were determined, respectively. Cell polarity related proteins, lost their specialized luminal localization in PMVECs of the CBDL rat. The loss of cell polarity was induced by abnormal activity of Cdc42, which was strongly enhanced by the interaction between p-PTEN and Annexin A2 in PMVECs, after treatment with serum from CBDL rats. It led to over-proliferation and high migration ability of PMVECs. Down-regulation of PTEN-Cdc42 activity in PMVECs restored cell polarity and thus reduced their ability of migration and proliferation. Our study suggested that the loss of cell polarity plays a critical role in the pathogenesis of HPS-associated PVR and may become a potentially effective therapeutic target.
Subject(s)
Cell Polarity , Hepatopulmonary Syndrome/metabolism , Hepatopulmonary Syndrome/pathology , PTEN Phosphohydrolase/metabolism , cdc42 GTP-Binding Protein/metabolism , Actin Cytoskeleton/metabolism , Animals , Annexin A2/metabolism , Cell Movement , Cell Proliferation , Cells, Cultured , Common Bile Duct/surgery , Endothelial Cells/metabolism , Endothelial Cells/pathology , Hepatopulmonary Syndrome/blood , Ligation , Lung/blood supply , Male , Microvessels/pathology , Models, Biological , Rats, Sprague-DawleyABSTRACT
BACKGROUND: Biliary cirrhosis is associated with hepatopulmonary syndrome (HPS), which is related to increased posttransplant morbidity and mortality. AIMS: This study aims to analyze the pathophysiology of biliary cirrhosis and the onset of HPS. METHODS: Twenty-one-day-old Wistar rats were subjected to common bile duct ligation and were allocated to two groups: group A (killed 2, 3, 4, 5, or 6 weeks after biliary obstruction) and group B (subjected to biliodigestive anastomosis 2, 3, 4, 5, or 6 weeks after the first procedure and killed 3 weeks later). At the killing, arterial blood was collected for the analyses, and samples from the liver and lungs were collected for histologic and molecular analyses. The gasometric parameters as well as the expression levels of ET-1, eNOS, and NOS genes in the lung tissue were evaluated. RESULTS: From a total of 42 blood samples, 15 showed hypoxemia (pO2 < 85 mmHg) and 17 showed an increased oxygen gradient [p (A-a) O2 > 18 mmHg]. The liver histology revealed increased ductular proliferation after common bile duct ligation, and reconstruction of bile flow promoted decreased ductular proliferation 5 and 6 weeks post-common bile duct ligation. Pulmonary alterations consisted of decreased parenchymal airspace and increased medial wall thickness. Biliary desobstruction promoted transitory improvements 5 weeks after biliary obstruction (increased parenchymal airspace and decreased MWT-p = 0.003 and p = 0.004, respectively) as well as increased endothelin expression levels (p = 0.009). CONCLUSIONS: The present model showed lung tissue alterations promoted by biliary obstruction. The biliodigestive anastomosis had no clear direct effects on these alterations.
Subject(s)
Bile Ducts/pathology , Disease Models, Animal , Hepatopulmonary Syndrome/pathology , Liver Cirrhosis, Biliary/pathology , Anastomosis, Surgical/methods , Animals , Bile Ducts/surgery , Female , Hepatopulmonary Syndrome/blood , Ligation , Liver Cirrhosis, Biliary/blood , Lung/pathology , Male , Rats , Rats, WistarABSTRACT
The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown. We aimed to determine the effect of sorafenib on the alveolar-arterial oxygen gradient (AaPO2 ) at 3 months in patients with HPS. We performed a randomized, double-blind, placebo-controlled parallel trial of sorafenib in patients with HPS at 7 centers. A total of 28 patients with HPS were randomized to sorafenib 400 mg by mouth daily or a matching placebo in a 1:1 ratio. We found no statistically significant difference in the median change in AaPO2 from baseline to 12 weeks between the patients allocated to sorafenib (4.5 mm Hg; IQR, -3.8 to 7.0 mm Hg) and those allocated to placebo (-2.4 mm Hg; IQR, -4.8 to 8.2 mm Hg; P = 0.70). There was also no difference between the groups in terms of degree of intrapulmonary shunting by contrast echocardiography. Sorafenib significantly reduced circulating levels of angiogenic markers, including vascular endothelial growth factor receptors (P < 0.01) and TIE2-expressing M2 monocytes (P = 0.03), but it reduced the mental component scores of the Short Form 36 (P = 0.04), indicating a worse quality of life. In conclusion, sorafenib did not change the AaPO2 or other disease markers at 3 months in patients with HPS. Alternative antiangiogenic therapies or treatments targeting other pathways should be investigated.
Subject(s)
Hepatopulmonary Syndrome/drug therapy , Neovascularization, Pathologic/drug therapy , Protein Kinase Inhibitors/administration & dosage , Quality of Life , Sorafenib/administration & dosage , Biomarkers/blood , Double-Blind Method , Echocardiography , Female , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/diagnosis , Humans , Male , Middle Aged , Neovascularization, Pathologic/blood , Neovascularization, Pathologic/diagnosis , Placebos/administration & dosage , Placebos/adverse effects , Proof of Concept Study , Protein Kinase Inhibitors/adverse effects , Sorafenib/adverse effects , Treatment OutcomeSubject(s)
Bronchiolitis/etiology , Cyanosis/diagnostic imaging , Ductus Arteriosus, Patent/surgery , Hepatopulmonary Syndrome/diagnostic imaging , Portal Vein/abnormalities , Vascular Malformations/diagnosis , Bronchiolitis/blood , Bronchiolitis/diagnostic imaging , Cardiac Catheterization , Child, Preschool , Cyanosis/blood , Cyanosis/etiology , Ductus Arteriosus, Patent/diagnostic imaging , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/etiology , Humans , Hyperammonemia/etiology , Male , Tomography, X-Ray Computed , Ultrasonography/methods , Vascular Malformations/blood , Vascular Malformations/complicationsABSTRACT
AIM: To examine the medical status of children with biliary atresia (BA) surviving with native livers. METHODS: In this cross-sectional review, data collected included complications of chronic liver disease (CLD) (cholangitis in the preceding 12 mo, portal hypertension, variceal bleeding, fractures, hepatopulmonary syndrome, portopulmonary hypertension) and laboratory indices (white cell and platelet counts, total bilirubin, albumin, international normalized ratio, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase). Ideal medical outcome was defined as absence of clinical evidence of CLD or abnormal laboratory indices. RESULTS: Fifty-two children [females = 32, 62%; median age 7.4 years, n = 35 (67%) older than 5 years] with BA (median age at surgery 60 d, range of 30 to 148 d) survived with native liver. Common complications of CLD noted were portal hypertension (40%, n = 21; 2 younger than 5 years), cholangitis (36%) and bleeding varices (25%, n = 13; 1 younger than 5 years). Fifteen (29%) had no clinical complications of CLD and three (6%) had normal laboratory indices. Ideal medical outcome was only seen in 1 patient (2%). CONCLUSION: Clinical or laboratory evidence of CLD are present in 98% of children with BA living with native livers after hepatoportoenterostomy. Portal hypertension and variceal bleeding may be seen in children younger than 5 years of age, underscoring the importance of medical surveillance for complications of BA starting at a young age.
Subject(s)
Biliary Atresia/complications , Cholangitis/epidemiology , Esophageal and Gastric Varices/epidemiology , Fractures, Bone/epidemiology , Gastrointestinal Hemorrhage/epidemiology , Hepatopulmonary Syndrome/epidemiology , Hypertension, Portal/epidemiology , Adolescent , Biliary Atresia/blood , Biliary Atresia/surgery , Child , Child, Preschool , Cholangitis/etiology , Chronic Disease , Cross-Sectional Studies , Esophageal and Gastric Varices/blood , Esophageal and Gastric Varices/etiology , Female , Follow-Up Studies , Fractures, Bone/blood , Fractures, Bone/etiology , Gastrointestinal Hemorrhage/blood , Gastrointestinal Hemorrhage/etiology , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/etiology , Humans , Hypertension, Portal/blood , Hypertension, Portal/etiology , Liver/physiopathology , Liver/surgery , Liver Function Tests , Malaysia/epidemiology , Male , Portoenterostomy, HepaticABSTRACT
INTRODUCTION: Different blood gas criteria have been used in the diagnosis of hepatopulmonary syndrome (HPS). PATIENTS AND METHODS: Arterial blood gases were prospectively evaluated in 194 cirrhotic candidates for liver transplantation (LT) in the supine and seated position. Three blood gas criteria were analyzed: classic (partial pressure of oxygen [PaO2] < 70 mmHg and/or alveolar-arterial gradient of oxygen [A-a PO2] ≥ 20 mmHg), modern (A-a PO2 ≥ 15 mmHg or ≥ 20 mmHg in patients over 64) and the A-a PO2 ≥ threshold value adjusted for age. RESULTS: The prevalence of HPS in the supine and seated position was 27.8% and 23.2% (classic), 34% and 25.3% (modern) and 22.2% and 19% (adjusted for age), respectively. The proportion of severe and very severe cases increased in a seated position (11/49 [22.4%] vs 5/66 [7.6%], p = 0.02). No difference was observed in the pre-LT, post-LT and overall mortality in patients with HPS, regardless of the criteria used. CONCLUSION: Obtaining blood gas measurements in the supine position and the use of modern criteria are more sensitive for the diagnosis of HPS. Blood gas analysis with the patient seated detects a greater number of severe and very severe cases. The presence of HPS was not associated with an increase in mortality regardless of blood gas criterion used.
Subject(s)
Blood Gas Analysis/methods , Hepatopulmonary Syndrome/diagnosis , Adult , Aged , Echocardiography , Female , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/diagnostic imaging , Humans , Liver Transplantation , Male , Middle Aged , Prevalence , Prospective Studies , Supine Position , Survival AnalysisABSTRACT
We have established that annexin A2 (ANXA2) is an important factor in the experimental hepatopulmonary syndrome (HPS) serum-induced proliferation of pulmonary arterial smooth muscle cells (PASMCs). However, the detailed mechanism remains unclear. ANXA2 translocated to the caveolin-enriched microdomains (caveolae) in PASMCs upon HPS serum stimulation. The disruption of caveolae by Methyl-ß-cyclodextrin (MßCD) alleviated the caveolae recruitment of ANXA2 and the ANXA2-mediated activation of ERK1/2 and NF-κB, so that ANXA2-modulated PASMC proliferation was suppressed. The over-expression of Cav-1 resulted in the relocation of ANXA2 from caveolae and negatively regulated ERK1/2 and NF-κB activation, which inhibited the ANXA2-modulated PASMC proliferative behavior. These data indicate that caveolae function as a signaling platform for ANXA2-induced proliferative behavior and Cav-1 participates upstream of ANXA2 in the activation of ERK1/2 and NF-κB.
Subject(s)
Annexin A2/metabolism , Caveolae/metabolism , Caveolin 1/metabolism , Hepatopulmonary Syndrome/metabolism , Hepatopulmonary Syndrome/pathology , Myocytes, Smooth Muscle/pathology , Pulmonary Artery/pathology , Animals , Caveolin 1/chemistry , Cell Proliferation , Extracellular Signal-Regulated MAP Kinases/metabolism , Hepatopulmonary Syndrome/blood , Male , NF-kappa B/metabolism , Protein Domains , Rats, Sprague-Dawley , beta-CyclodextrinsABSTRACT
BACKGROUND: The natural history of intrapulmonary vascular dilations (IPVD) and their impact on patient outcomes in the setting of portal hypertension has only been described in small series. AIMS: To assess the development of hepatopulmonary síndrome (HPS) in patients with isolated IPVD and to evaluate outcomes of IPVD and HPS among patients evaluated for liver transplantation (LT). MATERIAL AND METHODS: Data from a prospective cohort of patients evaluated for LT with standardized screening for HPS were analyzed. IPVDs were defined as the presence of microbubbles in the left atrium > 3 cycles following right atrial opacification. HPS was defined as the presence of IPVD and hypoxemia (Alveolar-arterial gradient ≥ 15 mmHg) in the absence of concomitant cardiopulmonary disease. RESULTS: A total of 104 patients with negative contrast-enhanced echocardiogram (CE) were compared to 63 patients with IPVD and 63 patients with HPS. Only four patients were categorized as 'severe' HPS based on degree of hipoxemia (defined as PaO2 < 60 mmHg). Twenty IPVD patients were followed with ABG over a mean duration of 21 months (range 9-43), of whom 7 (35%) subsequently met HPS criteria. Overall unadjusted survival from the time of LT evaluation using multi-state survival models that accounted for pre- and post-LT time was not statistically different among the three groups (negative CE, IPVD, and HPS; p > 0.5). CONCLUSIONS: Patients with IPVD appear to have a substantial risk of developing oxygenation impairment over time and progress to HPS. In our cohort, survival in patients with HPS and isolated IPVD is not different when compared to those without IPVDs.
Subject(s)
Hepatopulmonary Syndrome/pathology , Hypertension, Portal/surgery , Hypoxia/blood , Liver Cirrhosis/surgery , Liver Transplantation , Lung/blood supply , Oxygen/blood , Adult , Biomarkers/blood , Chi-Square Distribution , Dilatation, Pathologic , Echocardiography , Female , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/diagnostic imaging , Hepatopulmonary Syndrome/mortality , Humans , Hypertension, Portal/blood , Hypertension, Portal/mortality , Hypertension, Portal/pathology , Hypoxia/diagnosis , Hypoxia/mortality , Liver Cirrhosis/blood , Liver Cirrhosis/mortality , Liver Cirrhosis/pathology , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Male , Middle Aged , Multivariate Analysis , Oximetry , Patient Selection , Predictive Value of Tests , Proportional Hazards Models , Prospective Studies , Pulmonary Circulation , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
Background Hepatopulmonary syndrome (HPS) occurs in 20â-â30â% of patients with cirrhosis and is associated with increased mortality. Cholestasis and accumulation of bile acids (BAs) play a major role in chronic liver disease. Aim We aimed to evaluate the clinical role of serum BAs in patients with HPS. Methods Seventy-four patients with cirrhosis were included in this prospective study. Marker for cholestasis as total and individual serum BAs, bilirubin, alkaline phosphatase (AP), and gamma-glutamyl transpeptidase (GGT) were analyzed in patients screened for HPS.âCriteria of HPS were fulfilled in 26 patients (35â%). Results In contrast to AP and GGT, bilirubin and serum BAs were significantly elevated in patients with HPS (median total BAs in HPS 83.5 µmol/L, IQR 43.1â-â148.9 vs. no HPS 26.9 µmol/L, 11â-â75.6; pâ<â0.001). Total BAs correlated with gas exchange by means of PaO2â/âAaPO2 (r: -0.28, pâ<â0.05; r: 0.24, pâ<â0.05) and portal pressure (r: 0.33, pâ<â0.05). BAs were associated with HPS independently severity of underlying liver disease (OR: 1.012, 95â% CI: 1.001â-â1.023, pâ<â0.05). Conclusion BA retention is associated with HPS and gas exchange abnormalities. Future studies should assess whether modulation of BAs signaling may impact the course of HPS.
Subject(s)
Bile Acids and Salts/blood , Hepatopulmonary Syndrome/etiology , Liver Cirrhosis/complications , Biomarkers/blood , Hepatopulmonary Syndrome/blood , Humans , Prospective StudiesABSTRACT
AIM: To investigate possible abnormalities of vasoactive compounds, nitrative stress, and antioxidant activity of paraoxonase (PONa) in human hepatopulmonary syndrome (HPS), we determined endothelin-1 (ET), nitric oxide (NOx) metabolites, PONa alongside crude plasma nitrotyrosine (NT) as surrogate marker of nitrative stress. MATERIAL AND METHODS: Liver cirrhosis (LC) patients with HPS (n = 12) were matched by age, sex, and Child-Pugh score to LC patients without HPS (n = 15) and to healthy controls (CTR) (n = 15); plasma NO2(-) (nitrite) (vascular metabolite), NO3(-) (nitrate) (inflammatory metabolite), and PONa were determined by a colorimetric assay, ET, and NT by immunoassays. RESULTS: HPS patients showed higher level of ET (p = 0.0002), NO2(-) (p = 0.002), NO3(-) (p = 0.0001), NT (p < 0.0001), and lower PONa (p = 0.0004) than CTR; post-hoc analysis revealed greater ET (p < 0.05) and NO3(-) (p < 0.005) in LC patients with HPS than in LC patients without HPS. NT correlated to Child-Pugh score within HPS (p = 0.04) and LC (p = 0.02). CONCLUSION: Our HPS patients are characterized by elevated plasma levels of ET and NOx metabolites and lower PONa. Reduced PONa alongside elevated NO3(-) and NT suggests that defective antioxidation may favor nitrative stress and both may be implicated in the pathogenesis of HPS.
Subject(s)
Aryldialkylphosphatase/blood , Hepatopulmonary Syndrome/blood , Liver Cirrhosis/complications , Nitrates/blood , Nitric Oxide/metabolism , Nitrites/blood , Aged , Biomarkers/blood , Cross-Sectional Studies , Endothelin-1/blood , Female , Humans , Italy , Male , Middle AgedABSTRACT
OBJECTIVE: Hepatopulmonary syndrome (HPS) is characterized by vascular dilatation and hyperdynamic circulation, while portopulmonary hypertension (POPH) is characterized by vasoconstriction with fibrous obliteration of the vascular bed. Vasoactive molecules such as nitric oxide (NO) are candidate factors for cirrhotic complications associated with these diseases. However, oxidative stress balance is not well characterized in HPS and POPH. The present objective is to investigate the oxidative stress and anti-oxidative stress balance and NO pathway balance in patients with potential HPS and POPH. METHODS: We recruited patients with decompensated cirrhosis (n=69) admitted to our hospital as liver transplantation candidates. Patients exhibiting partial pressure of oxygen lower than 80 mmHg and alveolar-arterial oxygen gradient (AaDO2) ≥15 mmHg were categorized as potentially having HPS (23 of 69 patients). Patients exhibiting a tricuspid regurgitation pressure gradient ≥25 mmHg were categorized as potentially having POPH (29 of 61 patients). Serum reactive oxygen metabolites were measured and anti-oxidative OXY-adsorbent test (OXY) were performed, and the balance of these tests was defined as the oxidative index. The correlation between these values and the clinical characteristics of the patients were assessed in a cross-sectional study. RESULTS: Potential HPS patients exhibited no correlation with oxidative stress markers. Potential POPH patients exhibited lower OXY (p=0.037) and higher oxidative index values (p=0.001). Additionally, the vascular NO synthase enzyme inhibiting protein, asymmetric dimethylarginine, was higher in potential POPH patients (p=0.049). The potential POPH patients exhibited elevated AaDO2, suggesting the presence of pulmonary shunting. CONCLUSION: Potential POPH patients exhibited elevated oxidative stress with decreased anti-oxidative function accompanied by inhibited NO production. Anti-oxidants represent a candidate treatment for potential POPH patients.
Subject(s)
Hepatopulmonary Syndrome/etiology , Hypertension, Pulmonary/etiology , Liver Cirrhosis/complications , Lung/physiopathology , Case-Control Studies , Female , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/physiopathology , Humans , Hypertension, Pulmonary/blood , Hypertension, Pulmonary/physiopathology , Liver Cirrhosis/blood , Liver Cirrhosis/physiopathology , Liver Transplantation/adverse effects , Male , Middle Aged , Oxidative Stress , VasodilationABSTRACT
It has been postulated that cirrhosis-related lung vasodilatation and the subsequent hepatopulmonary syndrome are partly explained by an increased estradiol level through an enhanced endothelial formation of nitric oxide (NO). In this study, we assessed whether the oestrogen receptor antagonist fulvestrant (F) improves cirrhosis-related lung abnormalities. Cirrhosis was induced in rats by chronic bile duct ligation (CBDL). Four groups were studied: CBDL, CBDL+F, sham, and sham+F. Histological, immunohistochemical, and Western blot analyses were performed on lung samples. In the lung, the endothelial NO synthase and the nitrotyrosine protein expressions were increased in CBDL as compared to sham rats. Both parameters were significantly reduced by fulvestrant in the CBDL rats. Surprisingly, the level of pVASP (an indirect marker of NO formation and action) was decreased in CBDL rats, and fulvestrant had no effect on this parameter. The level of the vascular endothelial growth factor, the diameter of small lung vessels, and the number of macrophages were increased in CBDL lungs in comparison with sham lungs, and these parameters were unaffected by fulvestrant treatment. In conclusion, fulvestrant may not be relevant to improve lung abnormalities in cirrhosis because NO may not be biologically active and because key events contributing to the lung abnormalities are not affected by fulvestrant.
Subject(s)
Estradiol/analogs & derivatives , Estrogen Receptor Antagonists/pharmacology , Hepatopulmonary Syndrome/prevention & control , Liver Cirrhosis, Biliary/drug therapy , Lung/drug effects , Animals , Cell Adhesion Molecules/metabolism , Disease Models, Animal , Estradiol/blood , Estradiol/pharmacology , Fulvestrant , Heme Oxygenase (Decyclizing)/metabolism , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/etiology , Hepatopulmonary Syndrome/pathology , Liver Cirrhosis, Biliary/blood , Liver Cirrhosis, Biliary/complications , Lung/blood supply , Lung/metabolism , Lung/pathology , Macrophages/drug effects , Macrophages/metabolism , Male , Microfilament Proteins/metabolism , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type III/metabolism , Phosphoproteins/metabolism , Phosphorylation , Rats, Wistar , Tyrosine/analogs & derivatives , Tyrosine/metabolism , Vascular Endothelial Growth Factor A/metabolismABSTRACT
BACKGROUND AND AIMS: Hepatopulmonary syndrome (HPS) affects 10-32 % of patients with cirrhosis and is defined by liver abnormalities, intrapulmonary vascular dilatations (IPVDs), and abnormal oxygenation. However, published criteria for abnormal oxygenation are inconsistent. We sought to evaluate variation in oxygenation over time and to compare various diagnostic criteria for validity, based on their diagnostic stability over time and ability to identify patients with clinically relevant findings. METHODS: We retrospectively analyzed oxygenation and diffusion capacity in patients with liver abnormalities and IPVDs who had ≥ 2 arterial blood gases (ABGs) at the University of Toronto or Universite de Montreal. We compared the performance of nine possible oxygenation criteria for HPS and for each explored whether validity improved when requiring two consecutive abnormal ABGs on different days. RESULTS: Mean PaO2 was 68.4 mmHg and annual within-patient coefficient of variation 6.3 % (58 patients). Applying published criteria, 8.6-15.5 % of patients initially diagnosed with HPS no longer met the criterion for HPS on a subsequent ABG (re-classified). Requiring two consecutive abnormal ABGs on different days: (1) reduced the proportion of re-classified patients (9/9 criteria); (2) identified patients with more rapid progression in hypoxemia and greater difference in rate of progression between HPS and non-HPS (7/9 criteria); and (3) identified patients with lower diffusion and a larger difference in diffusion between HPS and non-HPS (8/9 criteria). CONCLUSIONS: Oxygenation is variable in this population, and requiring two abnormal results might reduce misdiagnosis and better differentiate patients with and without HPS according to clinically relevant markers of disease.
Subject(s)
Hepatopulmonary Syndrome/blood , Oxygen/blood , Blood Gas Analysis , Female , Humans , Male , Middle Aged , Ontario , Quebec , Respiratory Function Tests , Retrospective StudiesABSTRACT
OBJECTIVE: To determine the changes in levels of D-dimer, prothrombin time (PT), fibrinogen (Fib), CD4 and CD8 in relation to hepatopulmonary syndrome (HPS) by using a rat model system and to assess the association with pathologic changes in lung. METHODS: Forty male Sprague-Dawley rats were divided into equal groups for modeling of cirrhosis and HPS. The two groups were assessed by blood gas analysis, standard biochemical tests to measure D-dimer, PT, Fib, CD4 and CD8, and pathological examination of lung tissues. RESULTS: The HPS rats showed significantly lower PaO2 than the cirrhosis rats (58.20+/-3.19 mmHg vs. 85.00+/-2.53 mmHg, P = 0.000). The HPS rats showed significantly higher levels of D-dimer, Fib and CD8 than the cirrhosis rats (0.39+/-0.09 mg/ml vs. 0.25+/-0.05 mg/ml, P = 0.000; 1.77+/-0.10 g/L vs. and 1.49+/-0.09 g/L, P = 0.010; 32.32+/-4.45/mm3 vs. 20.13+/-6.09/mm3, P = 0.014). The HPS rats showed significantly lower levels of PT, CD4 and CD4/CD8 than the cirrhosis rats (14.86+/-1.04 s vs. 16.23+/-0.75 s, P = 0.036; 20.45+/-3.86/mm3 vs. 26.75+/-5.32/mm3, P = 0.000; 0.64+/-0.09 vs. 1.32+/-0.13, P = 0.000). The lung tissues of the HPS rats showed microthrombosis in pulmonary vessels, which were not observed in lung tissues of the cirrhosis rats. CONCLUSION: HPS-related differential levels of D-dimer, PT, Fib, CD4, CD8 and CD4/CD8 may represent a biomarker profile suggestive of incidence of thromboembolism in lung.
Subject(s)
Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Hepatopulmonary Syndrome/blood , Liver Cirrhosis/blood , Prothrombin Time , Animals , CD4 Antigens/metabolism , CD4-CD8 Ratio , CD8 Antigens/metabolism , Disease Models, Animal , Lung/pathology , Male , Rats , Rats, Sprague-DawleyABSTRACT
BACKGROUND & AIMS: Hepatopulmonary syndrome is a complication of chronic liver disease resulting in increased morbidity and mortality. It is caused by intrapulmonary vascular dilations and arteriovenous connections with devastating influence on gas exchange. The pathogenesis is not completely understood but evidence mounts for angiogenesis. Aims of this study were to identify angiogenic factors in serum of patients with hepatopulmonary syndrome and to study the possibility to predict its presence by these factors. METHODS: Multiplex assays were used to measure the concentration of angiogenic factors in patients with (n = 30) and without hepatopulmonary syndrome (n = 30). Diagnosis was based on the presence of gas exchange abnormality and intrapulmonary vasodilations according to published guidelines. RESULTS: Patients with and without hepatopulmonary syndrome had similar MELD scores (median: 11.2 vs. 11.6; P = 0.7), Child-Pugh score (P = 0.7) and PaCO2 values (median: 35 vs. 37; P = 0.06). PaO2 and P(A-a) O2 gradient were significantly different (respectively median of 80 vs. 86, P = 0.02; and 24 vs. 16, P = 0.004). Based on area under the curve (AUC) data and P-values, the best predictors were vascular cell adhesion molecule 1 (VCAM1) (AUC = 0.932; P < 0.001) and intercellular adhesion molecule 3 (ICAM3) (AUC = 0.741; P = 0.003). Combining these factors results in an AUC of 0.99 (after cross-validation still 0.99). CONCLUSIONS: VCAM1 and ICAM3 might be promising biomarkers for predicting hepatopulmonary syndrome. Combining these factors results in an AUC of 0.99 and a negative predictive value of 100%. Determining the concentration of these biomarkers might be a screening method to detect hepatopulmonary syndrome. The use of these biomarkers should be validated in larger groups of patients.
Subject(s)
Antigens, CD/blood , Cell Adhesion Molecules/blood , Hepatopulmonary Syndrome/blood , Liver Cirrhosis/complications , Vascular Cell Adhesion Molecule-1/blood , Aged , Biomarkers/blood , Female , Humans , Logistic Models , Male , Middle AgedABSTRACT
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) and hepatopulmonary syndrome are disorders characterized by the development of multiple pulmonary arteriovenous malformations (PAVM). PRESENTATION OF THE HYPOTHESIS: COX2 may be at the origin of a cascade of pro inflammatory events to favour angiogenesis and PAVM development. TESTING THE HYPOTHESIS: HHT and hepatopulmonary syndrome mouse models may be used to show its effects on PAVM formation. Anti COX-2 therapy could also be tested in human individuals, particularly in patients presenting a hepatopulmonary syndrome or HHT with small PAVM. IMPLICATION OF THE HYPOTHESIS: PAVMs are one of the main causes of morbidity in patients presenting with HHT disease, owing to the risks of rupture as well as paradoxical embolism exposing to stroke and/or cerebral abscess. Percutaneous embolization has become the treatment of choice of PAVM. Anti COX2 may prevent from PAVM development and subsequent related complications and avoid either surgery and/or percutaneous embolization and thus subsequent related complication.
Subject(s)
Cyclooxygenase 2/metabolism , Hepatic Veins/physiopathology , Hepatopulmonary Syndrome/blood , Hepatopulmonary Syndrome/physiopathology , Liver/blood supply , Liver/enzymology , Telangiectasia, Hereditary Hemorrhagic/enzymology , Animals , Arteriovenous Fistula/physiopathology , Disease Models, Animal , Embolization, Therapeutic , Humans , Hypoxia/physiopathology , Inflammation/physiopathology , Liver/physiopathology , Mice , Neovascularization, Pathologic , Pulmonary Artery/abnormalities , Pulmonary Artery/physiopathology , Pulmonary Veins/abnormalities , Pulmonary Veins/physiopathology , Vascular Endothelial Growth Factor A/metabolismABSTRACT
OBJECTIVE: This study is to investigate the role of glucose-regulated protein 78 (GRP78) in the pulmonary microvascular remodeling during hepatopulmonary syndrome (HPS) development. METHODS: The rat models with liver cirrhosis and HPS were induced by multiple pathogenic factors for 4 to 8 wk. The concentrations of alanine transferase (ALT) and endotoxin in plasma were detected in the models, followed by the detection of GRP78 expression. RT-PCR, quantitative real-time PCR and Western blotting were employed to assess the mRNA and protein expression levels of vascular endothelial growth factor (VEGF), respectively. Immunohistochemistry staining was used to examine the expression of a specific vascular marker, factor VIII-related antigen (FVIII-RAg), and several cell proliferation- and apoptosis-related proteins, including CHOP/GADD153, caspase-12, Bcl-2 and nuclear factor (NF)-κB. RESULTS: The levels of endotoxin and ALT in plasma were gradually increased as the disease progressed, so did GRP78, which were in a positive correlation. The expression levels of VEGF (both mRNA and protein) and FVIII-RAg were significantly elevated in the HPS models, indicating active angiogenesis, which was also positively correlated with GRP78 expression. Furthermore, the expression levels of the pro-apoptotic proteins of CHOP/GADD153 and caspase-12 were dramatically decreased, while the anti-apoptotic proteins of Bcl-2 and NF-κB were significantly elevated, in the HPS models. There were also close correlation between these proteins and GRP78. CONCLUSIONS: Over-expression of GRP78 in lungs may be the critical pathogenic factor for HPS. Through promoting cell proliferation and survival and inhibiting apoptosis, GRP78 may promote the pulmonary microvascular remodeling in HPS pathogenesis. Our results provide a potential therapeutic target for clinical prevention and treatment for HPS and related complications.
Subject(s)
Heat-Shock Proteins/metabolism , Hepatopulmonary Syndrome/metabolism , Hepatopulmonary Syndrome/physiopathology , Alanine Transaminase/blood , Animals , Apoptosis/physiology , Caspase 12/metabolism , Disease Models, Animal , Hepatopulmonary Syndrome/blood , Lung/blood supply , Lung/metabolism , Lung/physiopathology , Male , NF-kappa B/metabolism , Rats , Rats, Wistar , Transcription Factor CHOP/metabolism , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolismABSTRACT
BACKGROUND: Hepatopulmonary syndrome is formed by a triad of liver disease, intrapulmonary vascular dilatation and changes in blood gases. This condition is present in 4-32% of patients with cirrhosis. AIM: To analyze the blood gas changes data of patients in liver-transplant waiting list. METHOD: Clinical data of 279 patients in liver transplantation waiting list in May 2013 were studied. Overall patient was analyzed by the demographic aspects, laboratorial and image findings on exams that determine lung disease (hypoxemia) in these cirrhotic patients. The mean values and standard deviations were used to examine normally distributed variables. RESULTS: There was a high prevalence of male patients (68%); the mean age was 51(± 5,89) years, and the predominant reason for listing was hepatitis C cirrhosis. The MELD score mean was 16 ± 5,89, without prioritization or special situation. The most common blood type was O in 129 cases (46%) and the mean of body max index was 25,94 ± 4,58. Regarding arterial blood gas tests was observed 214 patients with PaO2 <90 mmHg, 80 with PaO2 <80 mmHg and 39 with PaO2 <50 mmHg. In relation to O2 saturation, 50 patients had <90%, 33 <80% and 10 <50%. CONCLUSION: Was observed a high rate of hypoxemia in patients on waiting list liver transplant. Due to the high severity and morbidity, is suggested better monitoring and therapeutic support to hypoxemic patients on liver transplant waiting list.